ArticleScientific reports2024
Cognitive profile, neuroimaging and fluid biomarkers in post-acute COVID-19 syndrome.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Neurocognitive and psychological symptoms in post COVID-19 patients (PASC24): prospective cohort study protocol.BMJ open · 2026Observational
- Article
- Cognitive Trajectories After Hospitalization for COVID-19: A 36-Month Longitudinal Study.The Journal of neuropsychiatry and clinical neurosciences · 2026Article
- Investigating the Impact of COVID-19 on Cognitive Functions Through Event-Related Potentials Analysis.Noro psikiyatri arsivi · 2026Article
- Neuropeptide and cytokines expression in long COVID-19 related neuropsychological sequelae: insights into NK1R-mediated neuroinflammation andFrontiers in cellular neuroscience · 2026Article
- Longitudinal Monitoring of Brain Volume Changes After COVID-19 Infection Using Artificial Intelligence-Based MRI Volumetry.Diagnostics (Basel, Switzerland) · 2025Article
- Impact of COVID-19 pandemic on cognitive decline in community-dwelling older adults in Shanghai: a longitudinal study from 2010 to 2024.The Lancet regional health. Western Pacific · 2025Article
- Cognitive and Psychological Symptoms in Post-COVID-19 Condition: A Systematic Review of Structural and Functional Neuroimaging, Neurophysiology, and Intervention Studies.Archives of rehabilitation research and clinical translation · 2025Review
- Evidence of clinical and brain recovery in post-COVID-19 condition: a three-year follow-up study.Brain communications · 2025Article
- Serum angiotensin type-1 receptor autoantibodies and neurofilament light chain as markers of neuroaxonal damage in post-COVID patients.Frontiers in immunology · 2025Article
- A tablet-based intervention study to alleviate cognitive and psychological symptoms in patients with post-Covid-19 condition.Frontiers in psychology · 2025Article
- Evaluating contributions of neuropsychological, psychiatric, and inflammatory processes to the expression of cognitive symptoms in post-acute COVID-19 syndrome.Frontiers in psychiatry · 2025Article
- When fatigue and cognitive impairment persist- a neurological follow-up-study in patients with Post-COVID syndrome.Scientific reports · 2024Article
- Cognitive outcomes and psychological symptoms in an Italian cohort with post-acute COVID-19 condition (PACC).Heliyon · 2024Article
- Persistent Cerebral 18-FDG PET Changes in Patients With Long COVID Presenting With Fatigue and Post Exertional Malaise.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to characterize the cognitive profile of post-acute COVID-19 syndrome (PACS) patients with cognitive complaints, exploring the influence of biological and psychological factors. Participants with confirmed SARS-CoV-2 infection and cognitive complaints ≥ 8 weeks post-acute phase were included. A comprehensive neuropsychological battery (NPS) and health questionnaires were administered at inclusion and at 1, 3 and 6 months. Blood samples were collected at each visit, MRI scan at baseline and at 6 months, and, optionally, cerebrospinal fluid. Cognitive features were analyzed in relation to clinical, neuroimaging, and biochemical markers at inclusion and follow-up. Forty-nine participants, with a mean time from symptom onset of 10.4 months, showed attention-executive function (69%) and verbal memory (39%) impairment. Apathy (64%), moderate-severe anxiety (57%), and severe fatigue (35%) were prevalent. Visual memory (8%) correlated with total gray matter (GM) and subcortical GM volume. Neuronal damage and inflammation markers were within normal limits. Over time, cognitive test scores, depression, apathy, anxiety scores, MRI indexes, and fluid biomarkers remained stable, although fewer participants (50% vs. 75.5%; p = 0.012) exhibited abnormal cognitive evaluations at follow-up. Altered attention/executive and verbal memory, common in PACS, persisted in most subjects without association with structural abnormalities, elevated cytokines, or neuronal damage markers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.